Please select the option that best describes you:
Topics:
Hematologic Malignancies • Rheumatology • General Rheumatology • Multiple Myeloma • Immunology
Is there any possible mechanism of action to account for prolonged hypogammaglobulinemia following short term use of tocilizumab in an individual with smoldering myeloma?
No significant infections nor treatment with B cell depleting drugs.